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Abstract  
Non-ocular melanocytic neoplasia is considered uncommon in cats yet is routinely 
encountered in diagnostic pathology and recognized to exhibit a wide variation in 
biological behavior. Accurate prediction of clinical outcomes is challenging with no 
widely recognized prognostic criteria. Signalment and tumor location were 
retrospectively evaluated in 324 cats diagnosed with non-ocular melanocytic 
neoplasia, histologic features were described in 141 neoplasms and outcome data 
were available in 79 cases. Immunohistochemistry using Melan-A, PNL-2, COX-2 
and E-cadherin was performed in a subset (n=24). Multivariate analysis identified 
tumor site, mitotic count and the presence of intratumoral necrosis to be independent 
predictors of tumor-related death. Based on these findings we propose a novel 
histologic grading scheme in which non-ocular melanocytic neoplasms involving the 
lips, oral or nasal mucosa or nasal planum were considered high-grade if they fulfil 
one or both of the following criteria: at least 4 mitoses in 10 hpf or presence of 
intratumoral necrosis, and those arising elsewhere were considered high-grade if 
they fulfil both of the above criteria. Of 79 tumors with outcome data, 43 (54%) were 
low grade and 36 (46%) were high grade. The grading system had an 80% 
sensitivity and 92% specificity for predicting tumor-related death in this population of 
cats. Median survival for cats with low-grade tumors was not reached, and the 
median survival was 90 days for those with a high-grade tumor. PNL-2 and Melan-A 
were sensitive markers for feline non-ocular melanocytic neoplasia and, although not 
significantly associated with prognosis, a large proportion expressed COX-2 
suggesting a potential therapeutic role for COX-2 inhibitors.  
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Non-ocular melanocytic neoplasms  are often considered rare neoplasms in cats, 
reported to account for less than 1% of all feline oral neoplasms and approximately 
0.5% of feline cutaneous tumors.14 Nevertheless, these neoplasms continue to be 
frequently reported in the literature.2,3,4  Unlike in dogs,13 however, there are no 
defined prognostic features for feline non-ocular melanocytic neoplasms, making 
provision of prognostic information, as well as guiding treatment options, challenging 
to both the pathologist and clinician. In dogs, oral melanocytic neoplasms generally 
have a worse prognosis when compared to cutaneous melanocytic neoplasms14,15 
however this was not found to be the case in a recent study evaluating clinical 
outcome of non-ocular melanomas in cats.2 In addition to tumor location, histologic 
features including mitotic index, nuclear atypia and degree of pigmentation are used 
to ascertain whether prognosis is favorable, uncertain or poor in dogs with 
melanocytic neoplasia.13 Given the known examples of where the biological behavior 
of neoplastic disease in dogs and cats differ12 extrapolation of these parameters may 
not be appropriate for use in cats. In addition, the information currently available for 
prognostication of melanocytic neoplasia in dogs may be inadequate in cases where 
features of both a favorable and poor prognosis co-exist. Histologic grading has 
become a tool routinely utilized by veterinary pathologists for consistent and 
accurate assessment of the potential biological behavior for many neoplasms. Given 
the now-wide range of surgical, chemotherapeutic and radiotherapeutic treatment 
options available to animals, and the implications on the animal and owner, accurate 
diagnosis and information regarding prognosis is critical. Further to the lack of 
prognostic information available regarding the biological behavior of feline non-ocular 
melanocytic neoplasia accurate diagnosis can also be problematic, particularly 
where tumors are amelanotic. Melan-A and PNL-2 antibodies are routinely used for 
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diagnosis of amelanotic melanomas in dogs10 and the use of these markers in feline 
melanocytic neoplasia has also previously been described.2,11,17 Cyclooxygenase 2 
(COX-2), an enzyme involved in the synthesis of prostaglandins not normally 
expressed by melanocytes, has been shown to be expressed in canine melanocytic 
tumors8,9 and related to tumor localization, proliferation and overall survival.5 
Expression of COX-2 may suggest a role for non-steroidal anti-inflammatory drugs 
(NSAIDs), particularly COX-2 inhibitors, in the treatment of melanocytic neoplasia. E-
cadherin is a transmembrane protein responsible for forming junctions between 
melanocytes and neighboring keratinocytes.14,17 E-cadherin expression has recently 
been shown to increase in feline diffuse iris melanoma associated with metastatic 
disease.17 Conversely, in human malignant melanomas downregulation of E-
cadherin has been associated with metastasis.6  
We conducted a multi-institutional study to retrospectively evaluate available clinical, 
histopathologic and outcome data in cats diagnosed with NOMN in order to identify 
potential prognostic factors. Using this information, the final aim of this study was to 
devise a novel classification scheme to accurately predict outcome in cats diagnosed 
with NOMN. Additionally, a subset of feline NOMN’s were assessed for expression of 
Melan-A, PNL-2, COX-2 and E-cadherin in this study to determine sensitivity and 
potential associations with outcome. 
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Materials and Methods 
 
Animals and clinical data 
This retrospective study of client-owned cats utilized data obtained from two 
diagnostic veterinary histopathologic laboratories in the UK and was approved by the 
Clinical Research Ethical Review Board at The Royal Veterinary College (URN 2016 
1578). Cases were selected from the searchable electronic databases available at 
each diagnostic laboratory between 2006 and 2017. Inclusion criteria included cats 
from primary care veterinary practices with a histologic diagnosis of a melanocytic 
neoplasm that included either ‘melanocytic’, ‘melanocytoma’ or ‘melanoma’. All cats 
were grouped together as melanocytic neoplasms, regardless of whether the 
neoplasm was designated as benign or malignant in the original report.  All cats 
where lesions were intraocular were excluded. Where formalin fixed paraffin 
embedded (FFPE) tissue or hematoxylin-eosin (HE) stained tissue sections were 
available the histopathologic diagnosis of melanocytic neoplasia was reviewed. 
Histological and immunohistochemical evaluation was performed blinded to outcome 
data.  
The age, sex, neuter status and breed of each cat, as well as the location of the 
neoplasm and any relevant clinical features, were directly obtained from that 
recorded on the original histopathology report which was translated from the 
submission form completed by the primary veterinary practice. Follow-up data was 
obtained by telephone questionnaire with the primary practice. Cat coat color was 
recorded if known. The occurrence or absence of tumor-related death was recorded 
for outcome. Overall survival was recorded for all cats and defined as the time 
between histologic diagnosis and tumor-related death. Cats that were still alive at the 
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last time of follow-up or died (or were euthanized) due to unrelated causes were 
censored in the survival analysis. Cats whose records were not obtainable or that 
were not seen by the practice since the time of diagnosis were not included in the 
survival data. Any evidence of local recurrence, clinical staging or metastatic disease 
was also recorded. A total of 324 cats diagnosed with non-ocular melanocytic 
neoplasia were identified electronically to provide information on signalment and 
tumor location, histologic features were evaluated in 141 neoplasms where FFPE 
tissue or HE stained sections were available and outcome data was able to be 
obtained in 79 cases. In 24 cases where FFPE tissue was available 
immunohistochemistry was performed.  
Histopathology 
Tumors of all cases where FFPE tissue or HE stained tissue was available were 
included for histopathologic examination. The cases were evaluated simultaneously 
by two board certified pathologists (RP and SLP). Histopathologic examination was 
performed on 4µm thick sections stained with hematoxylin-eosin using light 
microscopy and confirmed the diagnosis of melanocytic neoplasia. Tumors were 
evaluated for the predominant histological pattern (cell type), percentage of 
neoplastic cells that contained melanin pigment, pigment intensity, nuclear atypia, 
cellular pleomorphism, mitotic count, the presence of intratumoral necrosis, surface 
ulceration, junctional activity and the presence of intraepithelial nests of neoplastic 
cells (Fig. 1-6). Sections were also evaluated for the presence or absence of tumor-
free histologic tissue margins (whether or not neoplastic cells extended to any of the 
histologic margins available) and evidence of vascular or lymphatic invasion. If 
required, bleached sections were examined to assess nuclear detail. If neoplastic 
cells were predominantly (>60%) polygonal and arranged in nests or cords these 
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were classified as epithelioid. If >60% of neoplastic cells were spindloid or elongate 
and formed streams or bundles these were classified as spindloid, and if both 
patterns were present in approximately equal proportions these were classified as 
mixed. If neoplastic cells were polygonal with a large volume of pale staining 
cytoplasm these were categorized as the balloon cell variant. Degree of 
pigmentation was recorded as the percentage (<50% =1, ≥ 50%=2) of neoplastic 
cells containing melanin pigment and pigment intensity (0 (no pigment) – 2 (high 
pigment)). These scores were then multiplied to give an overall pigmentation score. 
Nuclear atypia was subjectively graded as mild, moderate or marked (mild= 0-33%, 
moderate= 34-66%, and marked= 67-100% of neoplastic cells contained large, 
irregular and often multiple nucleoli) and given a score of 1, 2 or 3 respectively. 
Cellular pleomorphism according to variation in cell size and shape was also 
subjectively assessed as mild, moderate or marked and allocated a score of 1, 2 or 3 
respectively. A mitotic count consisted of the number of mitoses in 10 randomly 
selected, consecutive, non-overlapping (400x) HPF (2.37mm2) starting at an area of 
high mitotic activity and avoiding areas of ulceration or necrosis. Neoplasms were 
further grouped according to whether the mitotic count was <4 or ≥4. Intratumoral 
necrosis was defined as confluent aggregates of necrotic neoplastic cells and 
recorded as present or absent and excluded areas associated with ulceration. The 
presence of surface ulceration, junctional activity and intraepithelial nests of 
neoplastic cells were assessed where possible with junctional activity considered as 
neoplastic cells abutting the dermo-epidermal junction and intraepithelial nests being 
neoplastic cells forming nests within the overlying epithelium.  
Immunohistochemistry 
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Immunohistochemistry (IHC) was performed on cases where FFPE tissue was 
available. 4µm thick sections from representative blocks were mounted on to 
positively-charged slides (SuperFrost Plus, Menzel Gläser, Braunscheig, Germany). 
Antigen retrieval, labeling and counterstaining were performed on a Bond-Max 
Autostainer (Leica Biosystems, Newcastle-upon-Tyne, UK) using the Bond polymer 
refine detection system (Leica Biosystems). Primary antisera were specific for Melan-
A (A103 clone, monoclonal, Leica Microscopy, Milton Keynes, UK; 1 in 100 dilution; 
antigen retrieval in buffer pH 9.0 buffer [ER2, Leica Biosystems] for 20 min); PNL-2 
(sc-59306, monoclonal, Santa Cruz; 1 in 300 dilution; antigen retrieval in pH 6.0 
buffer [ER1, Leica Biosystems] for 20 min); COX-2 (SP21 clone, monoclonal Fisher 
Scientific, Loughborough, UK; 1 in 150 dilution; antigen retrieval pH 6.0 buffer [ER1, 
Leica Biosystems] for 10 min); and E-cadherin (NCH-38 clone, monoclonal, Agilent, 
Stockport, UK; 1 in 100 dilution; antigen retrieval in pH 6.0 buffer [ER1, Leica 
Biosystems] for 10 min). Sections from a canine oral melanocytic neoplasm, known 
to express Melan-A and PNL-2, was used as a positive control. Canine kidney was 
used as a positive control for COX-2 and normal feline skin as a positive control for 
E-cadherin. Negative controls were used where primary antibodies were replaced 
with normal serum.  
Immunolabeling characteristics for Melan-A and PNL-2 were characterized according 
to both the percentage of immunopositive cells and the intensity of labelling. The 
percentage of positively labelled neoplastic cells was recorded as 0= 5%, 1= 5-
10%, 2= 11-50%, and 3= >50%. Intensity was subjectively scored as 0= none, 1= 
mild, 2= moderate and 3= intense. Scores were then multiplied to give an overall 
score.10 COX-2 labeling was characterized according to percentage of positive 
neoplastic cells and intensity of labeling with 0= negative, 1= 1-19%, 2= 20-49%, 3= 
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>50% and 0= negative, 1= weak, 2= moderate and 3= strong. These were then 
multiplied to give a total immunoreactivity score.9 E-cadherin immunoreactivity was 
recorded according to the intensity of labelling (0= less than control, 1=control) and 
whether labelling was membranous and/or cytoplasmic. Areas adjacent to ulceration 
and/or necrosis were avoided for interpretation.  
Statistical analysis 
Statistical analysis was performed using SPSS Statistics (v. 23, IBM Corp). 
Differences were considered significant when P-value<.05. For survival analysis 
outcome was defined as time from histologic diagnosis to death due to melanocytic 
disease; cats that were still alive at the last time of follow-up or died/were euthanized 
due to unrelated causes were censored in the survival analysis and the time 
between diagnosis and follow-up or death recorded. Median survival time was 
estimated by the Kaplan-Meier method, and univariable and multivariable Cox 
proportional hazard model was used to identify significant prognostic factors. 
Multivariable Cox proportional hazard regression analysis was performed to include 
all of the significant variables identified in the univariable analysis, those with the 
highest p-values were sequentially excluded until the remaining variables all had p-
values of <0.05. For analysis, ages of cats were grouped into quartiles. Mitotic count 
was grouped into those cases with a mitotic count of <4 and those with a mitotic 
count of ≥4. Tumor location was grouped into ‘lip/oral/nasal’ or ‘other non-ocular’. A 
single case where the neoplasm was present within a lymph node was excluded for 
survival analysis. The data analysed in this study for all cats where outcome data 
was obtained are available as Supplemental Table S1.  
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Results 
Animals 
A total of 324 cats diagnosed with non-ocular melanocytic neoplasia were identified 
electronically to provide information on signalment and tumor location. Histologic 
features were evaluated in 141 neoplasms where FFPE tissue or HE stained 
sections were available. Outcome data was able to be obtained in 79 cases. In 24 
cases where FFPE tissue was available, immunohistochemistry was performed. 
Signalment and tumor location 
This study included 324 diagnoses of non-ocular melanocytic neoplasia  in cats. The 
age of the cats at the time of diagnosis ranged between 10 months and 20 years 
with the age of 11 cats not recorded (median 11 years, interquartile range 6 years). 
Of the 324 cats 167 (51.5%) were female, 146 (45.1%) were male and the majority 
of cats (261/324, 80.6%) were neutered with 11 cats being of unknown sex or neuter 
status. The breeds affected were domestic short hair (264/324, 81.4%), domestic 
long hair (29/324, 9.0%) or other breeds (Maine coon (5/324, 1.5%), British shorthair 
(5/324, 1.5%), Siamese (4/324, 1.2%) Burmese (3/324, 0.9%), ‘Domestic’ (2/324, 
0.6%), and Abyssinian, Bengal, Birman, British blue, Turkish Angora, Ragdoll, 
Persian, Persian X, Burmese X (each 1/324); 3/324 were of unknown breed. The 
most frequently affected anatomic locations included the pinna/ear (80/324; 24.7%), 
elsewhere on the skin of the head (66/324, 20.4%), the oral cavity (56/324, 17.3%) 
and the truncal skin (32/324, 9.9%), with the remainder affecting other locations 
including the lip (17/324, 5.2%), the limb skin (14/324, 4.3%), the nose (13/324, 
4.0%), digital skin (7/324, 2.2%) the conjunctiva or third eyelid (4/324, 1.2%), the tail 
(3/324, 0.9%), and prepuce (1/324, 0.3%). 6/324 (1.85%) were primarily diagnosed 
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within lymph nodes and 25/324 (7.7%) were described as being on the skin without 
further being specified. Of cats where follow up information was obtained 6/80 
(7.5%) were of unknown color with 33/74 (44.6%) black or black and white, 23/74 
(31.1%) ‘tabby’ or ‘tabby and white’, 7/74 (9.5%) tortoiseshell, 5/74 (6.8%) ginger or 
ginger and white, 2/74 (2.7%) grey, 2/74 (2.7%) white, 1/74 (1.4%) sealpoint and 
1/74 (1.4%) was brown. 
Clinical characteristics 
Of the 141 cases where FFPE or HE stained tissue was available, submission data 
was reviewed. Of these 59 (41.8%) were described or suggested as being 
macroscopically pigmented and 25/141 (17.7%) were described as being eroded or 
ulcerated. Of the 80 cases where follow-up information was obtained, 8 cases (10%) 
recorded some form of clinical staging which consisted of local lymph node 
assessment in 7 cases and chest radiographs in 1 case. All 7 cases where lymph 
node assessment was performed reported evidence of metastatic disease. 
Confirmed or suspected metastatic disease was reported in 16/80 (20%) cases.  
Histopathology 
Hematoxylin-eosin stained tissue was evaluated in 141 of the 324 cases where 
FFPE or HE stained tissue was available. Of the141 cases, 14 (9.9%) were 
amelanotic, with 7 of these affecting the oral cavity, 2 arising on the pinna and one 
each affecting the conjunctiva, lip, nose, skin of a limb and trunk. Mitotic count 
ranged from 0-133 per 10 HPF (2.37mm2). Epithelioid was the most common 
histologic pattern (81/141, 57.4%), with 48/141 (34%) being spindloid, 10/141 (7.1%) 
being mixed and 2/141 (1.4%) being the balloon cell variant. Histologic tissue 
margins were considered to be free of neoplastic cells in 82 (58%) of cases, with 
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incomplete margins in 59 (42%) of cases. In 6 cases (4.3%) lymphatic or vascular 
invasion was observed, 3 of which were in the oral cavity. Ulceration was present in 
94/141 cases (66.7%), and 110/141 (78%) were found to have junctional activity, 
with 14/141 (9.9%) having intraepithelial nests. Intratumoral necrosis was present in 
29/141 (20.6%) of cases.  
Clinical outcome and survival analysis 
Follow up data was available for 80 of the 141 cases (57%) in which histopathologic 
evaluation was performed. Cats that were lost to follow-up included cases where 
primary practice information was not available, the cat had not been seen at the 
practice since time of diagnosis, practice recording systems had changed and 
historical records were not retrievable, or where cats could not be found on the 
records system. Survival of all cats ranged from 4 days to >2022 days with a median 
survival time of 427 days. Of the 80 cats with follow-up 43 (53.8%) were euthanized 
or died of causes perceived to be related to their melanocytic disease with a median 
survival of 244 days (Fig. 7).  
Median survival of cats with melanocytic tumors arising within the oral cavity, lips or 
nose (n=25) was 83 days. Median survival time of cats with melanocytic neoplasia 
arising in the skin or digit was not reached with 15/51 (29.4%) undergoing tumor 
related death. Mean estimated survival was 1406 days. Median survival of 
conjunctival/third eyelid melanocytic tumors (n=3) was also not reached with a mean 
estimated survival of 555 days.  Clear histologic tissue margins were present in 
42/80 (52.5%) of cases, of which local recurrence was recorded in 10 cases (23.8%).  
The single case where the diagnosed melanocytic neoplasm was within a lymph 
node was excluded from additional survival analysis. Univariate Cox proportional 
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hazard regression analysis was performed on signalment and histologic criteria 
recorded (n=79). Age at diagnosis, tumor location, mitotic count, pigmentation score, 
nuclear atypia, intratumoral necrosis, ulceration, intraepithelial nests and tumor free 
histologic tissue margins were all significantly (p-value<0.05) associated with 
outcome (Table 1). Local recurrence was also significantly associated with outcome. 
Breed, sex and neuter status, coat color, histological pattern, cellular pleomorphism, 
junctional activity and the presence of lymphatic or vascular invasion were not 
significantly associated with outcome. 
Tumor location (lip/oral/nasal or other non-ocular), mitotic count (<4 or ≥4 per 10 
HPF) and intratumoral necrosis (presence or absence of) were identified to be 
independent predictors of survival in the multivariable analysis (Figs. 8-10). Based 
on these, a grading system was devised (Table 2) andeach non-ocular melanocytic 
neoplasm with follow-up data available was then graded according to these criteria. 
43 Of these neoplasms 43 were low grade and 36 were high grade. Median survival 
for low grade neoplasms was not reached with 18.1% (8/43) of cats dying or 
euthanized due to their melanocytic disease with an estimated mean survival of 1642 
days. Median survival for high grade neoplasms was 90 days with a mean of 124 
days and 92% (33/36) of cats dying or euthanized due to their melanocytic disease 
(Fig. 11). Sensitivity of the grading scheme, to identify those cats that were likely to 
die due to their melanocytic disease, was 80% with a specificity of 92%. The positive 
and negative predictive values of the grading scheme were 92% and 81% 
respectively. 
Immunohistochemistry 
Immunohistochemical labeling was performed on the 24 feline non-ocular 
melanocytic neoplasms where FFPE tissue was available (Fig. 12-17). 21/24 
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(87.5%) immunohistochemically labelled for Melan-A and 22/24 (91.7%) labelled for 
PNL-2. One neoplasm was negative for both (neoplastic cells however exhibited a 
low degree of pigmentation on HE staining, which identified the diagnosis). Total 
score for Melan-A expression was not significantly associated with outcome whereas 
PNL-2 score was significantly associated with outcome (p=0.035) with those with a 
higher PNL-2 more likely to die due to their tumor.  
15/24 (62.5%) exhibited labelling for COX-2 with no significant association between 
score and outcome. Labeling for E-cadherin was observed in 19/24 (79.2%) cases 
with 13/24 (54.2%) exhibiting a reduced labelling intensity compared to controls with 
no significant association with outcome. Of these 3/24 showed membranous 
labelling only and 16/24 showing membranous and/or cytoplasmic labelling. E-
cadherin intensity or distribution was not associated with outcome.  
Discussion 
The aim of this retrospective study was to identify clinical and histologic features of 
feline non-ocular melanocytic neoplasia associated with outcome. Any original 
classification as benign or malignant at the time of initial diagnosis was disregarded 
in this study due to a lack of defined criteria of malignancy for feline non-ocular 
melanocytic neoplasms and variability in terminology used, and therefore all tumors 
are referred to in this study as melanocytic neoplasms. Prospectively for feline non-
ocular melanocytic neoplasms the authors would recommend the restricted use of 
the term melanoma, or preferably malignant melanoma, to state a malignant 
designation where appropriate, such as where there is presence of intravascular 
invasion. A lesion considered to be benign should be designated melanocytoma. In 
frequent situations where benign or malignant biological behaviour is not clearly 
apparent the authors prefer the use of the umbrella term melanocytic neoplasm.  
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Assessment of signalment data from a large number of cats diagnosed with non-
ocular melanocytic neoplasms identified a wide age range to be affected with a 
predominance of middle aged to older cats. There was no apparent sex predilection 
and the majority of cats were neutered with the predominant breed affected being 
the domestic short haired cat, likely reflecting the general population in the UK. 
Common anatomic sites included the pinna and skin of the head as previously 
reported.4,14 The oral cavity was also a common site affected. Although there was no 
significant association between coat color and tumor-related death nearly half of all 
cats where coat color was recorded were either black or black and white, suggesting 
that pigmentation of the coat may predispose to development of melanocytic 
neoplasia. This is in contrast to white cats being predisposed to squamous cell 
carcinoma7 with only 2 of the cats in this study being described as white. A limitation 
in assessing this parameter is that it was only possible to obtain general coat color 
and thus it is not known what color the hair coat was specifically at the site of tumor 
development in those cats that were not of uniform color. Nevertheless a differential 
diagnosis of melanocytic neoplasia should be considered for masses arising on the 
skin of the head or within the oral cavity of cats, and particularly in those cats that 
are not white in color. Additionally, many of the neoplasms in this study (41.8%) were 
reported by the primary veterinarians to be grossly pigmented. The retrospective 
nature of this study, however, may mean that the true proportion that exhibit 
macroscopic pigmentation is likely to be higher. As the population of cats used in this 
study were from primary veterinary practices rather than from a referral population, 
the majority did not undergo any form of clinical staging with only 10% reporting 
either local lymph node assessment or imaging. In the majority of cases where 
staging was performed metastatic disease was reported, however selection bias 
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based on the clinical presentation of cats may overestimate the likelihood of 
metastasis in this study, with clinical evidence of metastatic spread initiating staging 
in these cases. A total of 20% of cases reported suspected or confirmed metastatic 
disease however given the inconsistent clinical staging and lack of histological 
confirmation of metastasis this number may be either an underestimation or an 
overestimation of the true metastatic rate.  
This study confirms a wide variation in the histologic appearance of non-ocular 
melanocytic neoplasms in cats. Although the epithelioid pattern was most common 
there was no significant association between pattern and outcome. Age of cats was 
significantly associated with outcome with older cats more likely to suffer from tumor 
related death. In this study, as shown in previous studies,4 a higher proportion of 
non-ocular melanocytic neoplasms affecting the pinna was observed in younger 
cats. It may be that neoplasms in this location, more likely to be in younger cats, are 
recognized earlier or more likely to be surgically resectable. Tumor location was also 
associated with outcome in our study population with those affecting the lips, nose or 
oral cavity having a poorer prognosis. This may be due to innate biological features 
of the neoplastic cells arising in these locations, with all of the melanocytic 
neoplasms in the oral cavity in this study having a mitotic count of ≥4, or may be due 
to the relative difficulty in achieving early diagnosis and/or surgical resection in these 
locations, with oral neoplasms largely being biopsied for diagnostic purposes rather 
than being completely excised. Mitotic count and presence of intratumoral necrosis 
were also associated with occurrence of tumor related death, with a higher mitotic 
rate and presence of intratumoral necrosis potentially suggesting more rapid growth. 
All of the cats with amelanotic tumors in our study population died due to their 
melanocytic disease, with degree of pigmentation significantly associated with 
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outcome. This supports the suggestion that poor pigmentation correlates with poor 
differentiation and a more aggressive biological behavior. Similarly, nuclear atypia 
was also associated with outcome but this was felt to be a more subjective 
parameter to assess and was susceptible to increased inter-observer variability. 
Interestingly the presence of intraepithelial nests was associated with outcome but 
junctional activity was not. Tumor free histologic margins and absence of recurrence 
were both associated with reduced likelihood of tumor related death. In this study it 
was not possible to standardize the sectioning technique due to the retrospective 
nature involving multiple institutions and this should be considered in any future 
prospective studies, in addition to further recording the size of tumor-free histologic 
tissue margins where complete excision is achieved. Surprisingly the presence of 
lymphatic or vascular invasion was not significantly associated with outcome. 
However, of 5 cats with this feature and with follow-up information available, 4 died 
due to their melanocytic neoplasmand 1 died after a short period of time for an 
unrelated reason. Therefore the low number of cases in which this feature was 
observed may not have allowed identification of an association.  
Based on multivariable analysis, the tumor location, mitotic count and presence of 
any intratumoral necrosis were features used to devise a novel classification 
scheme. A 2-tiered grading scheme was favored to avoid the inclusion of an 
intermediate group where prognosis would remain uncertain. The grading scheme 
proposed here was able to identify 81% of cats that would die due to their 
melanocytic disease with 8% of those diagnosed as high grade not dying as a result 
of their tumor. Based on these results this grading scheme should identify the 
majority of non-ocular melanocytic neoplasms that are likely to exhibit aggressive 
biological behavior and thus warrant further staging and discussion regarding 
 19 
adjunctive therapy. In addition, the contrast in survival times between cats with 
tumors of each grade provides additional prognostic information not currently 
available. The parameters used in this grading scheme have been grouped in such a 
way as to minimize inter-pathologist variation and subjectivity.  
All of the cats in our study had surgical biopsy or excision only with no adjunctive 
chemotherapy or radiotherapy. A limitation of this study is the presumption that all 
cats alive at the time of follow up or deceased due to other causes would not have 
died due to their melanocytic neoplasia and ongoing prospective validation of this 
classification scheme is required. Survival data from our population of cats suggest 
an adequate follow up period of approximately 500 days to identify those cats that 
will suffer tumor related death.  
PNL-2 and Melan-A have been shown to be sensitive markers for feline non-ocular 
melanocytic neoplasms in our study. The one neoplasm that did not label with either 
marker also had no labelling of internal positive controls (adjacent non-neoplastic 
melanocytes) within the section, suggesting that the tissue may have been 
unsuitable for immunohistochemistry such as due to overfixation. A large proportion 
of tumors labelled for COX-2, as has been shown in canine melanocytic 
neoplasms8,9 however expression was not found to be associated with prognosis. E-
cadherin expression was reduced or lost in 75% of cases, suggesting down 
regulation of inter-cellular junctions and potentially enabling increased tumor growth, 
however was also not found to be a prognostic indicator. The lack of significant 
associations with outcome may be due to the small sample size used for 
immunohistochemical analysis.  
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For amelanotic tumors, where diagnosis may be challenging, both Melan-A and 
PNL-2 are sensitive markers to confirm melanocytic origin in cats. The significance 
of COX-2 and E-cadherin expression requires further investigation however a large 
proportion of melanocytic neoplasms in these cats expressed COX-2. Given the 
recognition of COX-2 inhibitors in the treatment of other tumors in both dogs and 
cats1 this suggests a potential new therapeutic option for the treatment of 
melanocytic disease in cats. Although aberrant cytoplasmic E-cadherin expression 
has been associated with a more aggressive behavior in skin neoplasms we cannot 
give further interpretation of these findings and future works should address the role 
of E-cadherin in non-ocular melanocytic neoplasms.16 
Based on this retrospective study we propose a novel 2-tier histologic classification 
scheme to more accurately predict those feline non-ocular melanocytic neoplasms 
that will exhibit aggressive biological behavior and are likely to result in tumor related 
death, potentially warranting further clinical staging and adjuvant therapy. 
Prospective use of this grading scheme on additional cases is required for further 
validation.  
 
  
 21 
Acknowledgements 
The authors would like to thank the laboratory staff involved in providing tissue 
sections required for this study.  
 
Conflict of Interest 
The author(s) declared no potential conflicts of interest with respect to the research, 
authorship, and/or publication of this article.  
 
Funding 
This work was supported by the Department of Pathobiology and Population 
Sciences at the Royal Veterinary College.  
 
  
 22 
References 
1.  Bommer NX, Hayes AM, Scase TJ, et al. Clinical features, survival times and COX-1 and COX-2 
expression in cats with transitional cell carcinoma of the urinary bladder treated with 
meloxicam. J Feline Med Surg. 2012;14(8):527-533. 
2.  Chamel G, Abadie J, Albaric O, et al. Non-ocular melanomas in cats: a retrospective study of 30 
cases. J Feline Med Surg 2017;19(4):351-357. 
3.  Day MJ, Lucke VM. Melanocytic neoplasia in the cat. J Small Animal Pract. 1995;36:207-213. 
4.  Luna LD, Higginbotham ML, Henry CJ, et al. Feline non-ocular melanoma: a retrospective study of 
23 cases (1991-1999). J Feline Med Surg. 2000;2(4):173-181. 
5.  Martinez CM, Penafiel-Verdu C, Vilafranca M, et al. Cyclooxygenase-2 expression is related with 
localization, proliferation, and overall survival in canine melanocytic neoplasms. Vet Pathol.  
2011;48(6):1204-1211. 
6.  McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human 
melanoma. Cancer Biol Ther. 2002;1(5):459-465. 
7.  Miller MA, Nelson SL, Turk JR, et al. Cutaneous neoplasia in 340 cats. Vet Pathol. 1991;28(5):389-
395. 
8.  Mohammed SI, Khan KN, Sellers RS, et al. Expression of cyclooxygenase-1 and 2 in naturally-
occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids. 2004;70(5):479-483. 
9.  Pires I, Garcia A, Prada J, et al. COX-1 and COX-2 expression in canine cutaneous, oral and ocular 
melanocytic tumours. J Comp Pathol. 2010;143(2-3):142-149. 
10.  Ramos-Vara JA, Miller MA. Immunohistochemical identification of canine melanocytic neoplasms 
with antibodies to melanocytic antigen PNL2 and tyrosinase: comparison with Melan A. Vet 
Pathol. 2011;48(2):443-450. 
11.  Ramos-Vara JA, Miller MA, Johnson GC,et al. Melan A and S100 protein immunohistochemistry in 
feline melanomas: 48 cases. Vet Pathol. 2002;39(1):127-132. 
12.  Sabattini S, Bettini G. Prognostic value of histologic and immunohistochemical features in feline 
cutaneous mast cell tumors. Vet Pathol. 2010;47(4):643-653. 
13.  Smedley RC, Spangler WL, Esplin DG, et al. Prognostic markers for canine melanocytic neoplasms: 
a comparative review of the literature and goals for future investigation. Vet Pathol. 
2011;48(1):54-72. 
14.  Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet 
Pathol. 2002;39(6):651-678. 
15.  Spangler WL, Kass PH. The histologic and epidemiologic bases for prognostic considerations in 
canine melanocytic neoplasia. Vet Pathol. 2006;43(2):136-149. 
16. Suárez-Bonnet A, Willis C, Pittaway R, et al. Molecular carcinogenesis in equine penile cancer: A 
potential animal model for human penile cancer. Urol Oncol. 2018; 36(12):532.e9-532.e18.  
17.  Wiggans KT, Reilly CM, Kass PH, et al. Histologic and immunohistochemical predictors of clinical 
behavior for feline diffuse iris melanoma. Vet Ophthalmol. 2016; 19 Suppl 1:44-55. 
 
 
 
 
 
 
 
 
 23 
 
Figure Legends 
 
Figures 1-6. Melanocytic neoplasms, cat. Hematoxylin and eosin. Figure 1. Skin. 
Epithelioid variant with polygonal neoplastic cells containing melanin pigment. Figure 
2. Skin. Spindle cell variant with elongate neoplastic cells forming streams. Figure 3. 
Nasal cavity. Balloon cell variant with neoplastic cells containing abundant pale-
staining cytoplasm. Figure 4. Skin Junctional activity with neoplastic cells abutting 
and infiltrating the epidermis (arrows).  Figure 5. Skin. Intratumoral necrosis with 
confluent aggregates of necrotic neoplastic cells (asterisk). Figure 6. Skin. Numerous 
mitotic figures (arrows).  
 
Figure 7. Kaplan-Meier survival curve for cats with non-ocular melanocytic neoplasia.  
 
Figures 8-11. Kaplan-Meier survival curves for cats with non-ocular melanocytic 
neoplasia according to tumor site, mitotic count, presence or absence of intratumoral 
necrosis, and histologic grade. Points indicate censored events. Overall survival 
according to location (lip/oral/nasal or other non-ocular; Fig. 8),  mitotic count (<4 or 
≥4 per 10 HPF; Fig. 9), presence or absence of intratumoral necrosis (Fig. 10). and 
histological grade using the proposed grading scheme (Fig 11). 
 
Figures 12-17. Melanocytic neoplasms, cat. Figure 12. Oral cavity. Strong 
immunolabelling for COX-2. Figure 13. Skin. Strong immunolabelling for Melan-A. 
Figure 14. Skin. Strong immunolabelling for PNL-2. Figures 15-17. Immunolabelling 
for E-cadherin.  Figure 15. Oral cavity. Surface keratinocytes exhibit membranous 
 24 
labelling (internal positive control). The subjacent neoplastic melanocytes are 
diffusely strongly positive. Figure 16. Skin. Membranous labelling of neoplastic 
melanocytes. Figure 17. Oral cavity. Cytoplasmic labelling of neoplastic 
melanocytes.  
